News

Review top news and interview highlights from the week ending November 11, 2022.

Data from the COBALT-RCC study in renal cell carcinoma were presented at SITC 2022.

The CRIPSR-edited neoantigen-specific T cell therapy demonstrated safety and feasibility in the first-in-human PACT-0101 study presented at SITC 2022.

Further analysis will be performed to elucidate which characteristics correlate with optimal cell therapy behavior.

The FDA action follows a slew of recent cell and gene therapy updates in the field of amyotrophic lateral sclerosis.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Several of the first cohort patients have had their Cell Pouch implants for over 3 years and no patients have elected to have their implants removed.

The director of translational research in myeloma at the Tisch Cancer Institute discussed the relevance of the new research as more CAR T therapies come to market.

Recent communication with the FDA suggests that the agency's decision might be delayed past Q1 2023.

Preclinical research in an OTOF-knockout mouse model demonstrated reversal of deafness.

No treatment-related adverse events have been reported and Verve expects a letter detailing the hold within 30 days.

The trial was launched through a partnership between Cure Rare Disease and UMass Chan Medical School.

The assistant professor of Hematologic Oncology and Blood Disorders at Atrium Health discussed integrating CAR T therapy into treatment paradigms.

The platform is capable of producing lentiviral vectors for preclinical, clinical, and commercial scales with high titers ranging from 1x10^8 TU/ml to 1x10^9 TU/ml.

The chair of gynecologic oncology at Moffitt Cancer Center gave an overview of a phase 1 trial being conducted at Moffitt Cancer Center.

Review top news and interview highlights from the week ending November 4, 2022.

AlloStem will be evaluated in the CELZ-201 clinical trial for patients with newly diagnosed type 1 diabetes.

Abeona has announced topline results from its phase 3 VIITAL study of EB-101.

Updated data from the ALTITUDE trial were presented at the 55th ARS meeting in Pasadena, CA.

Data from the first 2 patients were presented at the IWWM 2022 meeting.

Neurotech has announced updated data from protocol A and B phase 3 studies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The chair of gynecologic oncology at Moffitt Cancer Center discussed advantages of targeting follicle stimulating hormone receptor with cell therapy for ovarian cancer.

The DSMB has recommended the trial to continue with additional risk mitigation procedures.

The medical oncologists at Washington University School of Medicine in St. Louis discussed surprising findings from their retrospective study.

Studies have demonstrated positive data that suggest in vivo gene editing will be the future treatment paradigm for retinal diseases.

Cellular Biomedicine group developed the therapy after efficacy was seen with Iovance’s lifilecuel in solid tumor studies.

The pediatrician from Royal Manchester Children’s Hospital discussed how further research in Gaucher disease can benefit the field of rare lysosomal diseases as a whole.